Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
01
02
2023
received:
16
11
2022
accepted:
07
02
2023
medline:
15
6
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible, EGFR-tyrosine kinase inhibitor that potently and selectively inhibits EGFR-sensitizing and T790M resistance mutations with efficacy in EGFRm NSCLC including central nervous system (CNS) metastases. The open-label phase I positron emission tomography (PET) and magnetic resonance imaging (MRI) study (ODIN-BM) assessed [
Identifiants
pubmed: 36808835
doi: 10.1111/cts.13500
pmc: PMC10264937
doi:
Substances chimiques
osimertinib
3C06JJ0Z2O
ErbB Receptors
EC 2.7.10.1
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
955-965Informations de copyright
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
J Cereb Blood Flow Metab. 2020 Apr;40(4):799-807
pubmed: 31006308
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
Clin Cancer Res. 2021 Jan 1;27(1):189-201
pubmed: 33028591
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76
pubmed: 26902828
Neuro Oncol. 2018 Apr 9;20(5):589-596
pubmed: 29474640
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
Trends Pharmacol Sci. 2006 Jun;27(6):310-6
pubmed: 16678917
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
J Neurooncol. 2017 Nov;135(2):413-418
pubmed: 28780743
Int J Neuropsychopharmacol. 2015 Mar 26;18(10):pyv036
pubmed: 25813017
Lung Cancer. 2015 Apr;88(1):108-11
pubmed: 25682925
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
EJNMMI Res. 2015 Apr 30;5:30
pubmed: 25977884
J Nucl Med. 2018 Jun;59(6):973-979
pubmed: 29175983
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Neuro Oncol. 2021 Apr 12;23(4):687-696
pubmed: 33123736
Acta Psychiatr Scand Suppl. 1990;358:67-71
pubmed: 1978494
JCO Precis Oncol. 2021 Apr 01;5:
pubmed: 34095710
J Oncol Pract. 2018 Oct;14(10):e612-e620
pubmed: 30216125
Clin Transl Sci. 2023 Jun;16(6):955-965
pubmed: 36808835
Oncol Res Treat. 2016;39(7-8):461-3
pubmed: 27486808
Ann Oncol. 2018 Mar 1;29(3):687-693
pubmed: 29293889